A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

This Phase III study is testing a new antibody-drug treatment called YL201 in people with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat) that has come back or spread, and has stopped responding to standard treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed recurrent or metastatic nasopharyngeal carcinoma - Your cancer has already failed treatment with immunotherapy and at least two rounds of chemotherapy - You have at least one measurable tumor on scans - Your overall health is good (ECOG 0 or 1) **You may NOT be eligible if...** - You have had another cancer in the past 5 years - You have previously received B7-H3-targeted therapy - You have active brain, spinal cord, or meningeal metastases - You have active hepatitis B, hepatitis C, or HIV - You are pregnant or breastfeeding - You have active autoimmune disease requiring ongoing treatment Talk to your doctor to see if this trial is right for you.